Livagen (20 mg Vial) Dosage Protocol
Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator targeting lymphoid tissue, studied in Russian protocols for immune function, B-cell activity, and hematopoietic support.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (500 mcg) | 7.5 units (0.075 mL) |
| Weeks 3–4 | 1.0 mg (1000 mcg) | 15 units (0.15 mL) |
| Weeks 5–6 | 1.5 mg (1500 mcg) | 22.5 units (0.225 mL) |
| Weeks 7–12 | 2.0 mg (2000 mcg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to yield measurable volumes on standard insulin syringes. For ≤10-unit (≤0.10 mL) administrations (e.g., the initial 7.5-unit dose), consider 30- or 50-unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Livagen, 20 mg each) | 8 weeks ≈ 4 vials 12 weeks ≈ 7 vials 16 weeks ≈ 10 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Protocol Overview
The hypothesized gene-expression mechanism produces effects that persist months after the cycle ends, supporting the cycled rather than continuous approach. Evidence base is primarily Russian gerontology and clinical research; peer-reviewed Western data is limited.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
Livagen is a Khavinson-class peptide bioregulator hypothesized to modulate lymphoid gene expression and B-cell maturation, supporting humoral immunity.
Potential Benefits & Side Effects
Potential Benefits
- Lymphoid / B-cell immune support in Russian clinical protocols.
- Studied for age-related lymphoid decline.
- Complements Vilon for broad immune-modulation protocols.
Side Effect Profile
- Generally well-tolerated in Russian clinical literature.
- Mild injection-site reactions.
- Limited peer-reviewed Western data.
Lifestyle Factors
- Adequate sleep and rest during cycles.
- Balanced nutrition supports cellular repair.
Injection Technique
- Subcutaneous, rotate sites daily during 20-day cycle.